カテゴリ： 世界, 医療/バイオ, QYResearch

循環器疾患看護薬の世界市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬

■ 英語タイトル：Global Cardiovascular Disease Nursing Drugs Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8714）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8714
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：95
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥435,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥652,500見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥870,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[循環器疾患看護薬の世界市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料は循環器疾患看護薬のグローバル市場について調査・分析し、世界の循環器疾患看護薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬）、用途別セグメント分析（病院、医学研究所、診療所、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Crestor、Zetia、Vytorin、Letairis、Tracleer、Bystolic、Opsumit、Ranexa、Azilva、Remodulinなどが含まれています。循環器疾患看護薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、循環器疾患看護薬市場規模を算出する際に考慮しました。

・循環器疾患看護薬市場の概要
- 製品の定義
- 循環器疾患看護薬の種類別セグメント
- 世界の循環器疾患看護薬市場規模：タイプ別分析（降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬）
- 循環器疾患看護薬の用途別セグメント
- 世界の循環器疾患看護薬市場規模：用途別分析（病院、医学研究所、診療所、その他）
- 世界の循環器疾患看護薬市場規模予測（2018年-2029年）
- 循環器疾患看護薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 循環器疾患看護薬市場の競争状況およびトレンド

・循環器疾患看護薬の地域別市場規模
- 北米の循環器疾患看護薬市場規模（2018年-2029年）
- 米国の循環器疾患看護薬市場規模（2018年-2029年）
- ヨーロッパの循環器疾患看護薬市場規模（2018年-2029年）
- アジア太平洋の循環器疾患看護薬市場規模（2018年-2029年）
- 中国の循環器疾患看護薬市場規模（2018年-2029年）
- 日本の循環器疾患看護薬市場規模（2018年-2029年）
- 韓国の循環器疾患看護薬市場規模（2018年-2029年）
- インドの循環器疾患看護薬市場規模（2018年-2029年）
- オーストラリアの循環器疾患看護薬市場規模（2018年-2029年）
- 中南米の循環器疾患看護薬市場規模（2018年-2029年）
- 中東・アフリカの循環器疾患看護薬市場規模（2018年-2029年）

・種類別セグメント：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬
- 世界の循環器疾患看護薬のタイプ別販売量（2018年-2023年）
- 世界の循環器疾患看護薬のタイプ別売上（2018年-2023年）
- 世界の循環器疾患看護薬のタイプ別価格

・用途別セグメント：病院、医学研究所、診療所、その他
- 世界の循環器疾患看護薬の用途別販売量（2018年-2023年）
- 世界の循環器疾患看護薬の用途別売上（2018年-2023年）
- 世界の循環器疾患看護薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Crestor、Zetia、Vytorin、Letairis、Tracleer、Bystolic、Opsumit、Ranexa、Azilva、Remodulin

・産業チェーンと販売チャネルの分析
- 循環器疾患看護薬産業チェーン分析
- 循環器疾患看護薬の主要原材料
- 循環器疾患看護薬の販売チャネル
- 循環器疾患看護薬のディストリビューター
- 循環器疾患看護薬の主要顧客

・循環器疾患看護薬市場ダイナミクス
- 循環器疾患看護薬の業界動向
- 循環器疾患看護薬市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global Cardiovascular Disease Nursing Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cardiovascular Disease Nursing Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cardiovascular Disease Nursing Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cardiovascular Disease Nursing Drugs include Crestor, Zetia, Vytorin, Letairis, Tracleer, Bystolic, Opsumit, Ranexa and Azilva, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cardiovascular Disease Nursing Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Disease Nursing Drugs.
The Cardiovascular Disease Nursing Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiovascular Disease Nursing Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiovascular Disease Nursing Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Crestor
Zetia
Vytorin
Letairis
Tracleer
Bystolic
Opsumit
Ranexa
Azilva
Remodulin
Segment by Type
Antihypertensive Drugs
Antianginal Drugs
Anticoagulants
Antilipidemic Drugs
Anti-heart Failure Drugs
Antiarrhythmic Drugs
Segment by Application
Hospital
Institute of Medicine
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cardiovascular Disease Nursing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cardiovascular Disease Nursing Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Cardiovascular Disease Nursing Drugs Market Overview
1.1 Product Overview and Scope of Cardiovascular Disease Nursing Drugs
1.2 Cardiovascular Disease Nursing Drugs Segment by Type
1.2.1 Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Antihypertensive Drugs
1.2.3 Antianginal Drugs
1.2.4 Anticoagulants
1.2.5 Antilipidemic Drugs
1.2.6 Anti-heart Failure Drugs
1.2.7 Antiarrhythmic Drugs
1.3 Cardiovascular Disease Nursing Drugs Segment by Application
1.3.1 Global Cardiovascular Disease Nursing Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Institute of Medicine
1.3.4 Clinic
1.3.5 Others
1.4 Global Cardiovascular Disease Nursing Drugs Market Size Estimates and Forecasts
1.4.1 Global Cardiovascular Disease Nursing Drugs Revenue 2018-2029
1.4.2 Global Cardiovascular Disease Nursing Drugs Sales 2018-2029
1.4.3 Global Cardiovascular Disease Nursing Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cardiovascular Disease Nursing Drugs Market Competition by Manufacturers
2.1 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Cardiovascular Disease Nursing Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Cardiovascular Disease Nursing Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Product Type & Application
2.7 Cardiovascular Disease Nursing Drugs Market Competitive Situation and Trends
2.7.1 Cardiovascular Disease Nursing Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cardiovascular Disease Nursing Drugs Players Market Share by Revenue
2.7.3 Global Cardiovascular Disease Nursing Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cardiovascular Disease Nursing Drugs Retrospective Market Scenario by Region
3.1 Global Cardiovascular Disease Nursing Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cardiovascular Disease Nursing Drugs Global Cardiovascular Disease Nursing Drugs Sales by Region: 2018-2029
3.2.1 Global Cardiovascular Disease Nursing Drugs Sales by Region: 2018-2023
3.2.2 Global Cardiovascular Disease Nursing Drugs Sales by Region: 2024-2029
3.3 Global Cardiovascular Disease Nursing Drugs Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2018-2029
3.3.1 Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2018-2023
3.3.2 Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2024-2029
3.4 North America Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.4.1 North America Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.4.3 North America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.5.1 Europe Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.5.3 Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.7.1 Latin America Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.7.3 Latin America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cardiovascular Disease Nursing Drugs Sales by Type (2018-2029)
4.1.1 Global Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023)
4.1.2 Global Cardiovascular Disease Nursing Drugs Sales by Type (2024-2029)
4.1.3 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2029)
4.2 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2018-2029)
4.2.1 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2018-2023)
4.2.2 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2024-2029)
4.2.3 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Cardiovascular Disease Nursing Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cardiovascular Disease Nursing Drugs Sales by Application (2018-2029)
5.1.1 Global Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023)
5.1.2 Global Cardiovascular Disease Nursing Drugs Sales by Application (2024-2029)
5.1.3 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2029)
5.2 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2018-2029)
5.2.1 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2018-2023)
5.2.2 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2024-2029)
5.2.3 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Cardiovascular Disease Nursing Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Crestor
6.1.1 Crestor Corporation Information
6.1.2 Crestor Description and Business Overview
6.1.3 Crestor Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Crestor Cardiovascular Disease Nursing Drugs Product Portfolio
6.1.5 Crestor Recent Developments/Updates
6.2 Zetia
6.2.1 Zetia Corporation Information
6.2.2 Zetia Description and Business Overview
6.2.3 Zetia Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Zetia Cardiovascular Disease Nursing Drugs Product Portfolio
6.2.5 Zetia Recent Developments/Updates
6.3 Vytorin
6.3.1 Vytorin Corporation Information
6.3.2 Vytorin Description and Business Overview
6.3.3 Vytorin Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Vytorin Cardiovascular Disease Nursing Drugs Product Portfolio
6.3.5 Vytorin Recent Developments/Updates
6.4 Letairis
6.4.1 Letairis Corporation Information
6.4.2 Letairis Description and Business Overview
6.4.3 Letairis Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Letairis Cardiovascular Disease Nursing Drugs Product Portfolio
6.4.5 Letairis Recent Developments/Updates
6.5 Tracleer
6.5.1 Tracleer Corporation Information
6.5.2 Tracleer Description and Business Overview
6.5.3 Tracleer Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Tracleer Cardiovascular Disease Nursing Drugs Product Portfolio
6.5.5 Tracleer Recent Developments/Updates
6.6 Bystolic
6.6.1 Bystolic Corporation Information
6.6.2 Bystolic Description and Business Overview
6.6.3 Bystolic Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bystolic Cardiovascular Disease Nursing Drugs Product Portfolio
6.6.5 Bystolic Recent Developments/Updates
6.7 Opsumit
6.6.1 Opsumit Corporation Information
6.6.2 Opsumit Description and Business Overview
6.6.3 Opsumit Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Opsumit Cardiovascular Disease Nursing Drugs Product Portfolio
6.7.5 Opsumit Recent Developments/Updates
6.8 Ranexa
6.8.1 Ranexa Corporation Information
6.8.2 Ranexa Description and Business Overview
6.8.3 Ranexa Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ranexa Cardiovascular Disease Nursing Drugs Product Portfolio
6.8.5 Ranexa Recent Developments/Updates
6.9 Azilva
6.9.1 Azilva Corporation Information
6.9.2 Azilva Description and Business Overview
6.9.3 Azilva Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Azilva Cardiovascular Disease Nursing Drugs Product Portfolio
6.9.5 Azilva Recent Developments/Updates
6.10 Remodulin
6.10.1 Remodulin Corporation Information
6.10.2 Remodulin Description and Business Overview
6.10.3 Remodulin Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Remodulin Cardiovascular Disease Nursing Drugs Product Portfolio
6.10.5 Remodulin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cardiovascular Disease Nursing Drugs Industry Chain Analysis
7.2 Cardiovascular Disease Nursing Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cardiovascular Disease Nursing Drugs Production Mode & Process
7.4 Cardiovascular Disease Nursing Drugs Sales and Marketing
7.4.1 Cardiovascular Disease Nursing Drugs Sales Channels
7.4.2 Cardiovascular Disease Nursing Drugs Distributors
7.5 Cardiovascular Disease Nursing Drugs Customers
8 Cardiovascular Disease Nursing Drugs Market Dynamics
8.1 Cardiovascular Disease Nursing Drugs Industry Trends
8.2 Cardiovascular Disease Nursing Drugs Market Drivers
8.3 Cardiovascular Disease Nursing Drugs Market Challenges
8.4 Cardiovascular Disease Nursing Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Cardiovascular Disease Nursing Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Cardiovascular Disease Nursing Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Cardiovascular Disease Nursing Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Cardiovascular Disease Nursing Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Cardiovascular Disease Nursing Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Cardiovascular Disease Nursing Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cardiovascular Disease Nursing Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiovascular Disease Nursing Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cardiovascular Disease Nursing Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Cardiovascular Disease Nursing Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Cardiovascular Disease Nursing Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Cardiovascular Disease Nursing Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Cardiovascular Disease Nursing Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Cardiovascular Disease Nursing Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Cardiovascular Disease Nursing Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Cardiovascular Disease Nursing Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Cardiovascular Disease Nursing Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Cardiovascular Disease Nursing Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Cardiovascular Disease Nursing Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Cardiovascular Disease Nursing Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Cardiovascular Disease Nursing Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Cardiovascular Disease Nursing Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Cardiovascular Disease Nursing Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Cardiovascular Disease Nursing Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Cardiovascular Disease Nursing Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Cardiovascular Disease Nursing Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Cardiovascular Disease Nursing Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Cardiovascular Disease Nursing Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Cardiovascular Disease Nursing Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Cardiovascular Disease Nursing Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Type (2018-2023)
Table 59. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Type (2024-2029)
Table 60. Global Cardiovascular Disease Nursing Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Cardiovascular Disease Nursing Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Cardiovascular Disease Nursing Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Cardiovascular Disease Nursing Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Application (2018-2023)
Table 69. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Application (2024-2029)
Table 70. Crestor Corporation Information
Table 71. Crestor Description and Business Overview
Table 72. Crestor Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Crestor Cardiovascular Disease Nursing Drugs Product
Table 74. Crestor Recent Developments/Updates
Table 75. Zetia Corporation Information
Table 76. Zetia Description and Business Overview
Table 77. Zetia Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Zetia Cardiovascular Disease Nursing Drugs Product
Table 79. Zetia Recent Developments/Updates
Table 80. Vytorin Corporation Information
Table 81. Vytorin Description and Business Overview
Table 82. Vytorin Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Vytorin Cardiovascular Disease Nursing Drugs Product
Table 84. Vytorin Recent Developments/Updates
Table 85. Letairis Corporation Information
Table 86. Letairis Description and Business Overview
Table 87. Letairis Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Letairis Cardiovascular Disease Nursing Drugs Product
Table 89. Letairis Recent Developments/Updates
Table 90. Tracleer Corporation Information
Table 91. Tracleer Description and Business Overview
Table 92. Tracleer Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Tracleer Cardiovascular Disease Nursing Drugs Product
Table 94. Tracleer Recent Developments/Updates
Table 95. Bystolic Corporation Information
Table 96. Bystolic Description and Business Overview
Table 97. Bystolic Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bystolic Cardiovascular Disease Nursing Drugs Product
Table 99. Bystolic Recent Developments/Updates
Table 100. Opsumit Corporation Information
Table 101. Opsumit Description and Business Overview
Table 102. Opsumit Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Opsumit Cardiovascular Disease Nursing Drugs Product
Table 104. Opsumit Recent Developments/Updates
Table 105. Ranexa Corporation Information
Table 106. Ranexa Description and Business Overview
Table 107. Ranexa Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Ranexa Cardiovascular Disease Nursing Drugs Product
Table 109. Ranexa Recent Developments/Updates
Table 110. Azilva Corporation Information
Table 111. Azilva Description and Business Overview
Table 112. Azilva Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Azilva Cardiovascular Disease Nursing Drugs Product
Table 114. Azilva Recent Developments/Updates
Table 115. Remodulin Corporation Information
Table 116. Remodulin Description and Business Overview
Table 117. Remodulin Cardiovascular Disease Nursing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Remodulin Cardiovascular Disease Nursing Drugs Product
Table 119. Remodulin Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Cardiovascular Disease Nursing Drugs Distributors List
Table 123. Cardiovascular Disease Nursing Drugs Customers List
Table 124. Cardiovascular Disease Nursing Drugs Market Trends
Table 125. Cardiovascular Disease Nursing Drugs Market Drivers
Table 126. Cardiovascular Disease Nursing Drugs Market Challenges
Table 127. Cardiovascular Disease Nursing Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cardiovascular Disease Nursing Drugs
Figure 2. Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Cardiovascular Disease Nursing Drugs Market Share by Type in 2022 & 2029
Figure 4. Antihypertensive Drugs Product Picture
Figure 5. Antianginal Drugs Product Picture
Figure 6. Anticoagulants Product Picture
Figure 7. Antilipidemic Drugs Product Picture
Figure 8. Anti-heart Failure Drugs Product Picture
Figure 9. Antiarrhythmic Drugs Product Picture
Figure 10. Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 11. Global Cardiovascular Disease Nursing Drugs Market Share by Application in 2022 & 2029
Figure 12. Hospital
Figure 13. Institute of Medicine
Figure 14. Clinic
Figure 15. Others
Figure 16. Global Cardiovascular Disease Nursing Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Cardiovascular Disease Nursing Drugs Market Size (2018-2029) & (US$ Million)
Figure 18. Global Cardiovascular Disease Nursing Drugs Sales (2018-2029) & (K Units)
Figure 19. Global Cardiovascular Disease Nursing Drugs Average Price (US$/Unit) & (2018-2029)
Figure 20. Cardiovascular Disease Nursing Drugs Report Years Considered
Figure 21. Cardiovascular Disease Nursing Drugs Sales Share by Manufacturers in 2022
Figure 22. Global Cardiovascular Disease Nursing Drugs Revenue Share by Manufacturers in 2022
Figure 23. The Global 5 and 10 Largest Cardiovascular Disease Nursing Drugs Players: Market Share by Revenue in 2022
Figure 24. Cardiovascular Disease Nursing Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 25. Global Cardiovascular Disease Nursing Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. North America Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2029)
Figure 27. North America Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2029)
Figure 28. United States Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Canada Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Europe Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2029)
Figure 31. Europe Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2029)
Figure 32. Germany Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Cardiovascular Disease Nursing Drugs Sales Market Share by Region (2018-2029)
Figure 38. Asia Pacific Cardiovascular Disease Nursing Drugs Revenue Market Share by Region (2018-2029)
Figure 39. China Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. China Taiwan Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Latin America Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2029)
Figure 49. Latin America Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2029)
Figure 50. Mexico Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Brazil Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Argentina Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Middle East & Africa Cardiovascular Disease Nursing Drugs Sales Market Share by Country (2018-2029)
Figure 54. Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue Market Share by Country (2018-2029)
Figure 55. Turkey Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. UAE Cardiovascular Disease Nursing Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Global Sales Market Share of Cardiovascular Disease Nursing Drugs by Type (2018-2029)
Figure 59. Global Revenue Market Share of Cardiovascular Disease Nursing Drugs by Type (2018-2029)
Figure 60. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Type (2018-2029)
Figure 61. Global Sales Market Share of Cardiovascular Disease Nursing Drugs by Application (2018-2029)
Figure 62. Global Revenue Market Share of Cardiovascular Disease Nursing Drugs by Application (2018-2029)
Figure 63. Global Cardiovascular Disease Nursing Drugs Price (US$/Unit) by Application (2018-2029)
Figure 64. Cardiovascular Disease Nursing Drugs Value Chain
Figure 65. Cardiovascular Disease Nursing Drugs Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗血栓剤のグローバル市場展望 2023年-2029年：抗凝固薬、抗血小板薬
  • 婦人科介護医薬品の世界市場2023年：避妊、婦人科感染症、女性感染症、閉経後疾患、婦人科がん、子宮内膜症
  • 抗感染症薬の世界市場2023年：抗菌薬、抗真菌薬、抗ウイルス薬、抗寄生虫薬
  • クローン病治療薬のグローバル市場展望 2023年-2029年：抗炎症剤、免疫系抑制剤、抗生物質、その他
  • 心臓血管疾患検査キットのグローバル市場展望 2023年-2029年：血清サンプル、血漿サンプル、全血サンプル
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8714 )"循環器疾患看護薬の世界市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬" (英文：Global Cardiovascular Disease Nursing Drugs Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。